Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 3 , Pages 271-275 , May 2008

Predicting PSA failure following salvage radiotherapy for a rising PSA post-prostatectomy: From the CaPSURE™ database

  • O. Kenneth Macdonald, M.D.

      Affiliations

    • Huntsman Cancer Hospital, Salt Lake City, UT 84112, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-801-581-2396; fax: +1-801-585-2666.
    • ,
  • Anthony V. D'Amico, M.D., Ph.D.

      Affiliations

    • Brigham and Women's Hospital, Boston, MA 02115, USA
    • ,
  • Natalia Sadetsky, M.D., M.P.H.

      Affiliations

    • University of California, San Francisco, CA 94115, USA
    • ,
  • Dennis C. Shrieve, M.D., Ph.D.

      Affiliations

    • Huntsman Cancer Hospital, Salt Lake City, UT 84112, USA
    • ,
  • Peter R. Carroll, M.D.

      Affiliations

    • University of California, San Francisco, CA 94115, USA

Received 9 February 2007 ,Revised 13 April 2007 ,Accepted 16 April 2007.

References 

  1. Miller DC, Hafez KS, Stewart A, et al. Prostate carcinoma presentation, diagnosis, and staging: An update form the National Cancer Data Base. Cancer. 2003;98:1169–1178
  2. Consensus statement: The management of clinically localized prostate cancer. National Institutes of Health Consensus Development Panel. In: NCI Monogr. 1988;p. 3–6
  3. D'Amico AV, Whittington R, Malkowicz SB, et al. Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: The basis for an adjuvant therapy trial. J Clin Oncol. 1997;15:1465–1469
  4. Amling CL, Bergstralh EJ, Blute ML, et al. Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point?. J Urol. 2001;165:1146–1151
  5. Ennis RD, Flynn SD, Fischer DB, et al. Preoperative serum prostate-specific antigen and Gleason grade as predictors of pathologic stage in clinically organ confined prostate cancer: Implications for the choice of primary treatment. Int J Radiat Oncol Biol Phys. 1994;30:317–322
  6. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433–439
  7. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–1597
  8. Catton C, Gospodarowicz M, Warde P, et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol. 2001;59:51–60
  9. Chawla AK, Thakral HK, Zietman AL, et al. Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: Analysis of efficacy and prognostic factors. Urology. 2002;59:726–731
  10. Garg MK, Tekyi-Mensah S, Bolton S, et al. Impact of post-prostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology. 1998;51:998–1002
  11. Katz MS, Zelefsky MJ, Venkatraman ES, et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol. 2003;21:483–489
  12. Macdonald OK, Schild SE, Vora SA, et al. Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy. J Urol. 2003;170:1833–1837
  13. Song DY, Thompson TL, Ramakrishnan V, et al. Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology. 2002;60:281–287
  14. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325–1332
  15. Taylor N, Kelly JF, Kuban DA, et al. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 2003;56:755–763
  16. Buskirk SJ, Pisansky TM, Schild SE, et al. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: Evaluation of prognostic factors and creation of a prognostic scoring system. J Urol. 2006;176:985–990
  17. Anscher MS, Clough R, Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: The first 10 years. Int J Radiat Oncol Biol Phys. 2000;48:369–375
  18. Cadeddu JA, Partin AW, DeWeese TL, et al. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol. 1998;159:173–177Discussion 177–8.
  19. Choo R, Hruby G, Hong J, et al. (IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2002;53:269–276
  20. Leventis AK, Shariat SF, Kattan MW, et al. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2001;19:1030–1039
  21. Macdonald OK, Schild SE, Vora SA, et al. Salvage radiotherapy for palpable, locally recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2004;58:1530–1535
  22. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: A randomized controlled trial (EORTC trial 22911). Lancet. 2005;366:572–578
  23. Wiegel T, Bottke D, Willich N, et al. Proceedings of the 2005 ASCO Annual Meeting (Phase III results of adjuvant radiotherapy (RT) vs. wait and see (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO 96-02/AUO AP 09/95)). J Clin Oncol. 2005;23:4513
  24. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA. 2006;296:2329–2335
  25. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187–220
  26. Ornstein DK, Colberg JW, Virgo KS, et al. Evaluation and management of men whose radical prostatectomies failed: Results of an international survey. Urology. 1998;52:1047–1054
  27. Grossfeld GD, Stier DM, Flanders SC, et al. Use of second treatment following definitive local therapy for prostate cancer: Data from the CaPSURE database. J Urol. 1998;160:1398–1404

☆ CaPSURE™ is funded by TAP Pharmaceutical. O.K.M. was a study scholar funded by the sponsor during the completion of this project. N.S. and P.R.C. are investigators funded by the sponsor.

 This work was presented as a Poster Discussion at the 2006 Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2–6, 2006.

PII: S1078-1439(07)00127-5

doi: 10.1016/j.urolonc.2007.04.006

Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 3 , Pages 271-275 , May 2008

Article Tools

* Image Usage & Resolution